Induction of mixed hematopoietic chimerism using fludarabine, low-dose TBI [total body irradiation], PBSC [peripheral blood stem cell] infusion and post-transplantation immunosuppression with cyclosporine and mycophenolate mofetil to be folllowed by donor lymphocyte infusion in older patients with chronic myeloid leukemia in chronic and accelerated phases: a multicenter study.

Trial Profile

Induction of mixed hematopoietic chimerism using fludarabine, low-dose TBI [total body irradiation], PBSC [peripheral blood stem cell] infusion and post-transplantation immunosuppression with cyclosporine and mycophenolate mofetil to be folllowed by donor lymphocyte infusion in older patients with chronic myeloid leukemia in chronic and accelerated phases: a multicenter study.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2013

At a glance

  • Drugs Ciclosporin (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2012 Actual initiation date changed from Nov 1997 to Aug 1997 as reported by ClinicalTrials.gov.
    • 08 May 2012 Planned end date changed from Sep 2006 to Mar 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top